Tautomycin

Tautomycin is a potent and selective protein phosphatase inhibitor that is produced by the bacterium Streptomyces verticillatus. It is known for its ability to inhibit protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A), which are key enzymes involved in the regulation of various cellular processes.

History[edit | edit source]

Tautomycin was first isolated from Streptomyces verticillatus in 1987 by a team of Japanese researchers. The compound was named after its unique tautomeric structure, which allows it to exist in multiple chemical forms.

Structure and Properties[edit | edit source]

Tautomycin is a small molecule with a complex structure that includes a macrocyclic lactone ring and a highly functionalized side chain. Its unique tautomeric structure allows it to exist in multiple chemical forms, which contributes to its potent inhibitory activity.

Biological Activity[edit | edit source]

Tautomycin is a potent inhibitor of protein phosphatases, particularly PP1 and PP2A. These enzymes are involved in the regulation of a wide range of cellular processes, including cell growth, differentiation, and apoptosis. By inhibiting these enzymes, tautomycin can affect these processes and potentially have therapeutic effects.

Therapeutic Potential[edit | edit source]

Due to its ability to inhibit key cellular enzymes, tautomycin has been studied for its potential therapeutic applications. It has shown promise in preclinical studies for the treatment of various types of cancer, including leukemia and solid tumors. However, further research is needed to fully understand its mechanism of action and potential side effects.

References[edit | edit source]

This biochemistry article is a stub. You can help WikiMD by expanding it.

‎

This pharmacology-related article is a stub. You can help WikiMD by expanding it.

‎

Tautomycin Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.